U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C4H6N4O3
Molecular Weight 158.1154
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Allantoin

SMILES

NC(=O)NC1NC(=O)NC1=O

InChI

InChIKey=POJWUDADGALRAB-UHFFFAOYSA-N
InChI=1S/C4H6N4O3/c5-3(10)6-1-2(9)8-4(11)7-1/h1H,(H3,5,6,10)(H2,7,8,9,11)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://tri-k.com/acloxa

Aldioxa is the generic name for the metal complex, dihydroxyaluminum allantoinate, which is hydrolyzed to allantoin and aluminium hydrate at the gastric mucosa. Aldioxa was approved in Japan to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. It was discovered, that aldioxa ameliorates delayed gastric emptying through its antagonistic activity on the α-2 adrenergic receptor. The most commonly reported adverse reactions include constipation.

Approval Year

1961
146
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Not Provided
504
BODYGLIDE FOR HER

Approved Use

helps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns.

Launch Date

2009
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Approved
8429
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Approved
8429
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Primary
Approved
8429
Unknown

Approved Use

protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.43 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9131540/
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
30 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9131540/
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.69 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9131540/
10 mg/kg 3 times / day steady-state, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALLANTOIN plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:15676
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:15676
ChemicalBook
CB3215461
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3215461
MolPort
MolPort-001-779-876
https://www.molport.com/shop/molecule-link/MolPort-001-779-876
eMolecules
476195
https://www.emolecules.com/cgi-bin/more?vid=476195
PubMed

PubMed

TitleDatePubMed
[Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions].
1994 Mar
Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia.
2015 Dec 1

Sample Use Guides

In Vivo Use Guide
Sources: file:///C:/Users/Mark/Desktop/info_20ALCLOXA.pdf
Antiperspirants, deodorants: Creams, spray, lossions: 0.25-0.5% Baby products: creams; powders: 0.2-0.5%
Route of Administration: Topical
In Vitro Use Guide
Sources: file:///C:/Users/Mark/Desktop/info_20ALCLOXA.pdf
In vitro Alcloxa inhibited formation and bacterial decomposition of pulverized human epidermal scales. The scales were obtained from patient with exfoliative dermatitis, characterized by a great deal of exudation. The scales were were pulverized in a Wiley mill, defatted with ether and suspended in a 0,2% Alcloxa solution.
Name Type Language
Allantoin
EP   HSDB   II   INCI   JAN   MART.   MI   USAN   USP   USP-RS   VANDF   WHO-DD  
INCI   USAN  
Official Name English
IDELALISIB METABOLITE M1A
Common Name English
ALLANTOIN [INCI]
Common Name English
ALLANTOIN [USP MONOGRAPH]
Common Name English
CORDIANINE
Common Name English
NSC-7606
Code English
PSORALON
Common Name English
Allantoin [WHO-DD]
Common Name English
ALWEXTIN
Brand Name English
ALLANTOIN [MART.]
Common Name English
(2,5-DIOXO-4-IMIDAZOLIDINYL)UREA
Systematic Name English
ALLANTOIN [HSDB]
Common Name English
ALLANTOIN [VANDF]
Common Name English
SD 101 [WHO-DD]
Common Name English
(±)-ALLANTOIN
Common Name English
ALLANTOIN [II]
Common Name English
ALLANTOIN [MI]
Common Name English
ALLANTOIN [JAN]
Common Name English
UREA, (2,5-DIOXO-4-IMIDAZOLIDINYL)-
Systematic Name English
ALLANTOIN [USAN]
Common Name English
5-UREIDOHYDANTOIN
Systematic Name English
DL-ALLANTOIN
Common Name English
SEPTALAN
Common Name English
ALLANTOIN [USP-RS]
Common Name English
ALLANTOIN [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29700
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
CFR 21 CFR 347.10
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
FDA ORPHAN DRUG 151001
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
DSLD 3892 (Number of products:4)
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
CFR 21 CFR 310.534
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
EU-Orphan Drug EU/3/13/1232
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
NCI_THESAURUS C29708
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
EPA PESTICIDE CODE 85701
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
Code System Code Type Description
DRUG BANK
DB11100
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
DRUG CENTRAL
4268
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
NCI_THESAURUS
C74277
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
HSDB
7490
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
WIKIPEDIA
ALLANTOIN
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
RS_ITEM_NUM
1012939
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID3020043
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
ECHA (EC/EINECS)
202-592-8
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
FDA UNII
344S277G0Z
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
EVMPD
SUB12779MIG
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
ChEMBL
CHEMBL593429
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
PUBCHEM
204
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
CAS
97-59-6
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
MERCK INDEX
m1520
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY Merck Index
NSC
7606
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
MESH
D000481
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
DAILYMED
344S277G0Z
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
SMS_ID
100000078014
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
CHEBI
15676
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY
RXCUI
508
Created by admin on Fri Dec 15 16:35:52 GMT 2023 , Edited by admin on Fri Dec 15 16:35:52 GMT 2023
PRIMARY RxNorm
ACTIVE MOIETY
Structure of Allantoin
PARENT (METABOLITE)
Structure of IDELALISIB
PARENT (METABOLITE)
Structure of NELARABINE
PARENT (METABOLITE)
Structure of URIC ACID
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966